Interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone.
The present study showed that published spectrophotometric and GLC methods for hydralazine in plasma do not distinguish between the drug and a major plasma metabolite, hydralazine pyruvic acid hydrazone. These methods involve the acid treatment of the sample, which hydrolyzes that hydrazone back to hydralazine. A specific GLC assay for the hydrazone was developed and involves its selective extraction from plasma and transformation to 3-trifluoromethyl-s-triazolo[3,4-a]phthalazine. This derivative could be sensitively measured by GLC using an electron-capture detector. With this procedure, it was shown that most "apparent hydralazine" in plasma is the hydrazone, which forms rapidly from hydralazine and endogenous pyruvic acid. Previous work indicated that the hydrazone was inactive when administered intravenously to rabbits.
D002849:Chromatography, Gas; D004355:Drug Stability; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives* / Q000097:blood*; D006835:Hydrazones / Q000097:blood; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D011773:Pyruvates / Q000097:blood; D013056:Spectrophotometry, Ultraviolet
D006835:Hydrazones; D011773:Pyruvates; D006830:Hydralazine